Toge T, Hirai T, Takiyama W, Takashima N, Kawano K, Tamura Y, Nishimawari K, Iwamori S, Nakanishi K, Kono H
Dept. of Surgical Oncology, Research Institute for Radiation Biology.
Gan To Kagaku Ryoho. 1995 Mar;22(4):539-46.
FUT-187 was orally administered to 38 patients with postgastrectomy reflux esophagitis for 4 weeks. The drug reduced the chief subjective symptoms of reflux esophagitis, such as heartburn, chest pain, precordial pain, and dysphagia for solids in 78.1% of patients. Redness, edema and erosion were also reduced in 53.3% of patients as determined endoscopically. Overall, FUT-187 exhibited an excellent therapeutic effect on the reflux esophagitis which was refractory to conventional treatments.
